Latest Patents News

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

Strategic Elements has achieved a significant milestone with the granting of a patent in Japan for its Energy Ink™ moisture energy platform, reinforcing its foothold in a critical electronics market and advancing its battery-free device ambitions.

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.

IperionX has won up to US$6.6 million from the US Department of War to scale production of ballistic-grade titanium plate and military components, aiming to reduce reliance on imports and strengthen domestic supply chains.

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.

49 Metals has confirmed and extended a high-grade gold feeder structure at its Gold Mountain project in Nevada, with drilling revealing significant gold mineralisation and promising signs of a larger epithermal system.

Bayan Mining has partnered with The University of Queensland to push forward its patented yttrium processing technology, aiming to validate and optimise the process using Australian rare earth feedstocks and support pilot-scale development.

Way2VAT has restructured its debt with Bank Hapoalim, securing a larger $4.876 million facility and extending loan terms to three years to support growth and approach breakeven.

ClearVue Technologies is inviting eligible shareholders to participate in a $1 million Share Purchase Plan at a discount, following a $5 million institutional placement. The capital raised will support ERP rollout, R&D, and working capital.

Calix's subsidiary Leilac has locked in a paid engineering study with an East Asian cement producer, advancing its commercial cement decarbonisation technology without capital outlay. This complements its recent Indian partnership and signals a strategic pivot to capital-light projects.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.